Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
A Multicenter Study in Patients Undergoing AnthRacycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
Sponsor: Alere San Diego
Listed as NCT01032278, this NA trial focuses on Cardiac Toxicity and Unspecified Adult Solid Tumor, Protocol Specific and remains ongoing. Sponsored by Alere San Diego, it has been updated 10 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting NA
-
Jun 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
▶ Show 5 earlier versions
-
Sep 2018 — Jun 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting NA
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alere San Diego
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .